Short answer: KPV is a small anti-inflammatory tripeptide (lysine-proline-valine) derived from alpha-MSH. It is a research-use-only compound, not an FDA-approved medicine. KPV free base and acetate are listed for discussion at the FDA’s July 23, 2026 compounding advisory committee meeting (evaluated uses: wound healing and inflammatory conditions) — a review for possible 503A Bulks List inclusion, which is not an approval.
KPV is one of the lesser-known names on the FDA’s July 2026 peptide agenda, sitting alongside higher-profile compounds like BPC-157 and TB-500. It does not get the same search volume, but it is scientifically interesting and increasingly discussed in inflammatory-research circles — which makes it worth a clear, research-framed explainer as the meeting approaches.
KPV is a tripeptide — just three amino acids: lysine (K), proline (P) and valine (V), hence the name. It is the C-terminal tripeptide fragment of alpha-melanocyte-stimulating hormone (alpha-MSH), a signalling peptide with a well-documented role in pigmentation and, importantly here, in modulating inflammation.
The research interest in KPV centres on the observation that this short fragment appears to retain much of alpha-MSH’s anti-inflammatory activity while being smaller and simpler. In laboratory and pre-clinical studies it is discussed in the context of inflammatory signalling pathways — which is why it shows up in research conversations around gut inflammation, skin and wound-healing models. As with every compound we cover, this is a description of research context, not a health claim.
Framing note. KPV is a research compound. Describing the research areas it appears in is not the same as saying it treats, cures or prevents anything. There are no approved human-use claims for KPV, and none should be implied.
KPV tends to come up in a few recurring research themes:
It is often grouped with other “repair and inflammation” research peptides, and is sometimes discussed alongside BPC-157 in that broad category — though the two are structurally and mechanistically distinct. For the most-searched repair compound, see our BPC-157 research guide.
On July 23, 2026, the FDA’s Pharmacy Compounding Advisory Committee is scheduled to discuss KPV bulk drug substances (free base and acetate), with wound healing and inflammatory conditions listed as the evaluated uses. The committee is reviewing whether these substances should be considered for the 503A Bulks List — the list relevant to traditional pharmacy compounding by licensed pharmacists or physicians.
As with the other compounds on the agenda, this is a compounding-policy review, not a drug-approval decision. A recommendation for inclusion would not make KPV an FDA-approved medicine. KPV appears on the same day as BPC-157, TB-500 and MOTS-c; the full line-up is in our FDA peptide review 2026 overview.
It is worth stating plainly, because KPV’s lower profile makes it especially prone to being mischaracterised if coverage picks up: the July 2026 meeting does not approve KPV, does not confirm it is safe and effective for any human use, and does not authorise human-use marketing. KPV remains a research-use-only compound before, during and after the meeting. The same “review ≠ approval” logic we apply to BPC-157 in Is BPC-157 FDA approved? applies equally to KPV.
Lower-profile compounds can be more exposed to sourcing problems, not less, because there is less public scrutiny and fewer reference points. For any KPV research, the documentation is what matters: third-party purity verification, a batch-specific Certificate of Analysis, accurate compound identification and clear research-use-only labelling. Treat “FDA-approved KPV” or human-use claims as red flags — neither is accurate.
What is KPV?
A tripeptide (lysine-proline-valine), the C-terminal fragment of alpha-MSH, studied for anti-inflammatory properties. It is a research-use-only compound.
Is KPV being reviewed by the FDA?
Yes — it is on the July 23, 2026 compounding advisory committee agenda (evaluated uses: wound healing and inflammatory conditions). That is a 503A compounding review, not a drug approval.
Is KPV FDA approved?
No. KPV is not an FDA-approved medicine; it is supplied as research-use-only material, not for human consumption.
Source: the FDA’s July 23–24, 2026 Pharmacy Compounding Advisory Committee meeting agenda. External links are provided for research reference only; New-U is not affiliated with these organisations and links carry no endorsement either way.
New-U Research Compounds supplies sealed 10-vial packs, independently verified by Janoshik and Freedom Diagnostics for >99% purity, with a Certificate of Analysis. Research use only - not for human consumption.
Browse the catalogAt New-U, we believe better conversations start with better information. For laboratory research use only. Not for human consumption.